

Zydus Cadila Healthcare Therapeutic and Drug Pipeline Review H2

Zydus Cadila Healthcare Treatment Pipeline Review H2 2017

PUNE, INDIA, February 1, 2017 /EINPresswire.com/ -- <u>Zydus Cadila</u> <u>Healthcare</u> Ltd - Product Pipeline Review - 2016

Summary

The report provides comprehensive information on the therapeutics under development by Zydus Cadila Healthcare Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the



descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/915296-zydus-cadila-healthcare-ltd-product-pipeline-review-2016 []

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Zydus Cadila Healthcare Ltd
- The report provides overview of Zydus Cadila Healthcare Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report assesses Zydus Cadila Healthcare Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Zydus Cadila Healthcare Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Zydus Cadila Healthcare Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Zydus Cadila Healthcare Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Zydus Cadila Healthcare Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points

Table of Contents 2

List of Tables 7

List of Figures 7

Introduction 8

Zydus Cadila Healthcare Ltd Snapshot 9

Zydus Cadila Healthcare Ltd Overview 9

Key Facts 9

Zydus Cadila Healthcare Ltd - Research and Development Overview 10

Key Therapeutic Areas 10

Zydus Cadila Healthcare Ltd - Pipeline Review 15

Pipeline Products by Stage of Development 15

Pipeline Products - Monotherapy 16

Pipeline Products - Combination Treatment Modalities 17

Pipeline Products - Partnered Products 18

Partnered Products/Combination Treatment Modalities 19

Zydus Cadila Healthcare Ltd - Pipeline Products Glance 20

Zydus Cadila Healthcare Ltd - Late Stage Pipeline Products 20

Pre-Registration Products/Combination Treatment Modalities 20

Phase III Products/Combination Treatment Modalities 21

Zydus Cadila Healthcare Ltd - Clinical Stage Pipeline Products 22

Phase II Products/Combination Treatment Modalities 22

Phase I Products/Combination Treatment Modalities 23

Zydus Cadila Healthcare Ltd - Early Stage Pipeline Products 24

Preclinical Products/Combination Treatment Modalities 24

Discovery Products/Combination Treatment Modalities 25

Zydus Cadila Healthcare Ltd - Unknown Stage Pipeline Products 26

Unknown Products/Combination Treatment Modalities 26

Zydus Cadila Healthcare Ltd - Drug Profiles 27

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus)

(pentavalent) vaccine - Drug Profile 27

...Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/915296-zydus-cadila-healthcare-ltd-product-pipeline-review-2016

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports <a href="https://twit

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.